Topotarget: Encouraging results with cancer treatment


The Danish biotech company Topotarget has very good results with the first tests of a treatment of advanced cancer, the company informed today.

The management of Topotarget is very pleased with the results of the Phase II studies of the PXD101. Topotarget cooperates with the American CuraGen on the development of the cancer drug.

"The results which we can present with the PXD101 strengthen our expectations for this new type of drug against cancer. PXD101 is well tolerated and seems to be well suited in combination with other cancer drugs used today. This admits a broad use of the drug," - CEO Peter Buhl Jensen, TopoTarget said.

Head of research at CuraGen, Timothy Shannon, believes that if everything is on track, it will be possible to present the cancer drug later this year and start the registration in 2008.

"The new results of our clinical development programme are very encouraging... The activity level we have noted with PXD101 in combination with generally used chemotherapeutic drugs for patients with advanced cancer proves how competitive our development programme is," - Timothy Shannon said.



Previous entry: "I Can Cope" Classes For Cancer Patients Start Nov. 7

Next entry: HK scientists identify cancer-blocking protein

Find recent content on the main index or look in the archives to find all content.